LAK CELLS AND IL 2 ADMINISTERED INREPERTITONEALLY FOR OVARIAN & COLORECTAL CANCER

淋巴因子激活的杀伤细胞和白介素2的研究 给癌症患者全身用药的研究表明，这是 一种针对特定恶性肿瘤的有效治疗方法。我们希望 推广了Rosenberg等人的初步观察结果。通过管理此 腹膜腔内治疗仅限于患者的疾病 腹腔炎。到目前为止，这包括卵巢癌患者。 结直肠癌合并腹膜癌的患者。全 对病人进行仔细的分期，以排除有疾病的病人。 在腹膜腔外。患者一次接受白介素2治疗 连续三天每八小时每公斤100,000个单位 在接受连续5天的白细胞分离之前。这些细胞 每天通过白细胞分离收集的数据被送到实验室，在那里他们 放入含有白介素2的培养中。在激活一周后 在体外，它们被用在患者的腹膜内。就在之前 LAK细胞的安装，白介素2的剂量为25000单位 按每公斤给药。然后注射相同剂量的IL-2 只要患者能耐受治疗，每八小时一次。

Studies with lymphokine activated killer cells and interleukin 2 administered systemically to patients with cancer have shown that this is an effective modality of therapy for selected malignancies. We wish to extend the initial observations of Rosenberg, et al. by administering this therapy intraperitoneally for patients who had disease limited to the abdominal cavity. So far this has included patients with ovarian cancer and patients with colorectal cancer with peritoneal carcinomatosis. All patients are staged carefully to exclude those patients with disease outside of the peritoneal cavity. Patients receive interleukin 2 at a dose of 100,000 units per kilogram every eight hours for three consecutive days prior to undergoing leukapheresis for five consecutive days. The cells collected by leukapheresis each day are sent to the laboratory where they are placed in culture with interleukin 2. After one week of activation in vitro, they are administered intraperiotoneally to patients. Just prior to the installation of the LAK cells, interleukin 2 at a dose of 25,000 unit per kilogram is administered. This same dose of IL 2 is then administered every eight hours as long as the patient tolerates therapy.